Biocryst Pharmaceuticals Inc (BCRX) - News Archive

Date : Insert Date Here In a significant strategic maneuver aimed at strengthening its foothold in the hereditary angioedema (HAE) treatment landscape, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has announced its dec...

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) has recently achieved a significant regulatory milestone with the approval of ORLADEYO (berotralstat) in Colombia. This approval marks an important step in expanding treatmen...

Unlocking Talent in Biotech: BioCryst Pharmaceuticals Grants Restricted Stock Units to New HiresIn a strategic move reflecting its commitment to attracting and retaining top talent, BioCryst Pharmaceuticals, Inc. (Nasda...

Recent advancements in the field of hereditary angioedema (HAE) prophylaxis have emerged, underscoring the critical need for safer, more effective treatment options for patients affected by this condition. BioCryst Phar...

BioCryst Pharmaceuticals Boosts Talent Acquisition with New Inducement GrantsBioCryst Pharmaceuticals, Inc. headquartered in Research Triangle Park, N.C. is charting a strategic course to enhance its workforce and drive...

BioCryst Pharmaceuticals, Inc. Embraces Growth with Strategic Inducement Grants: An Overview of Recent DevelopmentsBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), a company renowned for its innovations in drug developmen...

RESEARCH TRIANGLE PARK, N.C. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is making significant strides in treating hereditary angioedema (HAE), a debilitating genetic disorder characterized by recurrent episodes of se...

RESEARCH TRIANGLE PARK, N.C. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is making significant strides in its efforts to attract and retain top talent, as evidenced by a series of recent stock option and restricted st...

Long-Term Prophylactic Benefits of Berotralstat in Hereditary Angioedema: A Promising Future At the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting, BioCryst Pharmaceuticals is set to pre...

Strategic Moves and Inducements: BioCryst Pharmaceuticals Recent DevelopmentsBioCryst Pharmaceuticals, Inc. a prominent biotech firm headquartered in Research Triangle Park, North Carolina, recently announced a series o...

Title : Unlocking Hope: BioCryst Pharmaceuticals’ Groundbreaking Step Towards Treating Netherton Syndrome with BCX17725 :In the realm of rare genetic disorders, Netherton syndrome looms with its complex tapestry of symp...

Biocryst Pharmaceuticals Grants Stock Options and RSUs to New Employees in Accordance with Nasdaq RulesBiocryst Pharmaceuticals Inc (Nasdaq: BCRX) has recently announced the granting of stock options and restricted stoc...

Biocryst Pharmaceuticals Inc., a renowned biotechnology company, has recently announced inducement grants to newly hired employees. These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), include stock opt...

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 In a significant development for patients suffering from hereditary angioedema (HAE), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that the General Directorat...

Cultivating Talent: BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Hires, Impacts on Shareholders AnalyzedIn a recent press release, BioCryst Pharmaceuticals, Inc. announced the granting of stock options...

BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees, Faces Financial ChallengesBioCryst Pharmaceuticals, Inc. recently announced that the compensation committee granted stock options and restricted s...

BioCryst Pharmaceuticals, Inc. has recently presented new real-world evidence on the use of ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE) patients in the United States. The findi...

In a groundbreaking development, BioCryst Pharmaceuticals, Inc. has recently announced the approval of its oral, once-daily medication ORLADEYO (berotralstat) by the Federal Commission for Protection against Health Risk...

BioCryst s ORLADEYO Shows Promising Reductions in Healthcare Resource Utilization for Patients with HAE: A Breakthrough in HAE Treatment Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent...

BioCryst Pharmaceuticals Grants Stock Options and RSUs as Inducements to New Employees, Faces Challenges Amidst Cumulative Net Loss In a recent announcement, BioCryst Pharmaceuticals, Inc. revealed that the compensation...